StartUPDATES: New Developments from Healthcare Startups
Read about news from Carrum Health, New Enterprise Associates, American Medical Women's Association, and Iaso Therapeutics.
Read about news from Carrum Health, New Enterprise Associates, American Medical Women's Association, and Iaso Therapeutics.
In the runup to MedCity INVEST in Chicago, we're spotlighting the perspectives of investors and what motivates them to invest in startups. If you're a startup in pharma tech, value-based care and care coordination, diagnostics or remote patient monitoring/smart devices, apply to our Pitch Perfect contest today.
Read more to find out which finalists will present in the Home Health track of the startup pitch contest during the virtual conference, scheduled for September 20-23.
The insurance startup led by UnitedHealthcare’s former CEO closed a $635 million funding round led by New Enterprise Associates.
The deadline for applications to the Pitch Perfect competition at INVEST Digital Health in Minneapolis is approaching. Our judges for the contest offered their perspective for what makes or breaks a healthcare startup's pitch.
Gottlieb previously worked at NEA from 2007 to 2017, when he was appointed as commissioner of the FDA. He stepped down from that role in March, also returning to another previous employer, the American Enterprise Institute.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Big name executives including former GE CEO Jeff Immelt, former Yahoo CEO Marissa Mayer, LinkedIn CEO Jeff Weiner and Levi’s CEO Chip Bergh also made personal investments in the company as part of the Series B round led by NEA.
The company plans to the use the money to extend its reach into therapeutic area-related intelligence and outcomes-based contracting for payers.
From money-back guarantees to a surprising source of funding, MedCity INVEST presenters and panelists discussed some of the major trends influencing the biopharma sector in 2017.
It's safe to say Ed Mathers has accrued some industry know-how after 35 years in the biopharma industry — 15 of which have been spent on the investor side. So what's his take on today's high potential therapeutic areas?
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.